SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Intravenous anesthetic agents as far as inhaled agents produce a dose depended increase in latency and decrease in amplitude of SomatoSensory Evoked Potential (SSEP). Dexmetedomidine, a highly selective a2 adrenergic agonist, not only minimizes the anesthetic agents but also the opioids, reducing the analgesic demands. The effect of dexmedetomidine on SSEP has not been elucidated. We aimed to investigate alterations on somatosensory SSEP in adults during posterior spinal fusion surgery before and after Dexmedetomidine administration.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: George Papanicolaou Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients with ASA physical status 1-3

Exclusion Criteria:

• Patients with ASA physical status >3,

• Body Mass Index (BMI) over 30,

• indication for rapid sequence induction,

• any contraindication for receiving b-blocker,

• Glasgow Coma Scale (GCS) <13,

• history of drug abuse,

• neurologic deficit or preoperatively foreseen delayed extubation,

• preoperative heart rate<45.